{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:30:20Z","timestamp":1786977020390,"version":"build-2736575974"},"reference-count":12,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1435,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1002\/art.30502","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T16:03:05Z","timestamp":1308844985000},"page":"3163-3168","source":"Crossref","is-referenced-by-count":47,"title":["Clinical outcomes after withdrawal of anti-tumor necrosis factor \u03b1 therapy in patients with juvenile idiopathic arthritis: A twelve-year experience"],"prefix":"10.1002","volume":"63","author":[{"given":"Kevin","family":"Baszis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Garbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Toib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,27]]},"reference":[{"key":"10.1002\/art.30502-BIB1|cit1","first-page":"S105","article-title":"Remission in juvenile idiopathic arthritis","volume":"24","author":"Ravelli","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1002\/art.30502-BIB2|cit2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1002\/art.30502-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor \u03b1 blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30502-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30502-BIB5|cit5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30502-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30502-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30502-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/ard.2008.101030","article-title":"When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30502-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3899\/jrheum.100219","article-title":"Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis","volume":"37","author":"Remesal","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1002\/art.30502-BIB10|cit10","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1002\/art.30502-BIB11|cit11","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1002\/art.30502-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.090952","article-title":"Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents","volume":"36","author":"Russo","year":"2009","journal-title":"J Rheumatol"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30502","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30502","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/art.30502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T17:44:55Z","timestamp":1625075095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30502"}},"subtitle":["Withdrawal of Anti-TNF\u03b1 Therapy in JIA"],"short-title":[],"issued":{"date-parts":[[2011,9,27]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1002\/art.30502","archive":["Portico"],"relation":{},"ISSN":["0004-3591"],"issn-type":[{"value":"0004-3591","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9,27]]}}}